Valuation : iTeos Therapeutics, Inc.

Market Cap 449M 386M 362M 331M 619M 42.41B 624M 4.29B 1.67B 21.68B 1.68B 1.65B 69.81B P/E 2023
-3.48x
P/E 2024 -2.31x
Enterprise Value -40.87M -35.16M -33M -30.19M -56.35M -3.86B -56.79M -390M -152M -1.97B -153M -150M -6.36B EV / Sales 2023
-10,640,152x
EV / Sales 2024 -5,970,615x
Free-Float
100%
Yield 2023 *
-
Yield 2024 -
3 years 4.8
Extreme 4.8
18.75
5 years 4.8
Extreme 4.8
52.43
10 years 4.8
Extreme 4.8
52.43
Manager TitleAgeSince
Chief Executive Officer 59 27/08/2025
Chief Operating Officer - 27/08/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 59 27/08/2025
Date Insider Type Main position Quantity % Market Cap. Importance
29/08/25 Tender

Chief Technology Officer

222,423 0.5811%
29/08/25 Tender

Chief Executive Officer; Director

1,106,638 2.8914%
29/08/25 Tender

Chief Operating Officer

578,671 1.5119%
Change 5-day change 1-year change 3-year change Capi.($)
+0.20%-.--%-.--%-17.28% 449M
+0.41%-2.07%+41.26%+95.40% 69.02B
-0.96%+0.94%+43.11%+90.27% 66.32B
+0.04%+4.36%-11.72%+459.54% 27.66B
-0.90%-7.65%+2.45%-15.50% 25.84B
-3.00%-2.90%+39.40%+9.41% 26.54B
0.00%+1.90%+25.90%-17.50% 20.4B
+3.45%-13.46%+222.69%+389.50% 17.63B
-1.49%-4.88%-0.41%+530.26% 15.15B
+1.03%+7.00%+59.98%+160.03% 14.65B
Average -0.12%-1.24%+42.27%+168.41% 28.37B
Weighted average by Cap. -0.30%-0.83%+41.67%+148.11%

Financials

2023 2024
Net sales 12.6 10.84 10.17 9.3 17.37 1.19K 17.5 120.3 46.85 608.45 47.3 46.27 1.96K 35 30.11 28.26 25.86 48.26 3.31K 48.64 334.3 130.19 1.69K 131.43 128.57 5.45K
Net income -113M -96.92M -90.95M -83.21M -155M -10.65B -157M -1.08B -419M -5.44B -423M -414M -17.53B -134M -116M -109M -99.29M -185M -12.71B -187M -1.28B -500M -6.49B -505M -494M -20.91B
Net Debt -526M -452M -425M -388M -725M -49.71B -731M -5.02B -1.96B -25.4B -1.97B -1.93B -81.82B -490M -421M -395M -362M -675M -46.28B -680M -4.68B -1.82B -23.65B -1.84B -1.8B -76.17B
Logo iTeos Therapeutics, Inc.
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its EOS-984, a potentially first-in-class small molecule, focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1, a dominant transporter of extracellular adenosine, expressed on intratumoral T cells, which allows adenosine entry into the cell, disturbing T cell metabolism, expansion, effector function, and survival. It is also developing EOS-215, a potential best-in-class monoclonal antibody which antagonizes the triggering receptor expressed on myeloid cells 2.
Employees
173
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. ITOS Stock